Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.

Last updated: January 14, 2025
Sponsor: Nantes University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Macular Degeneration

Myopic Macular Degeneration

Aging

Treatment

Faricimab

Clinical Study ID

NCT06271330
AP_JBD_FarWest_004
  • Ages > 18
  • All Genders

Study Summary

Age-related macular degeneration (AMD) is a degenerative retinal disease. The prognosis of the exudative form was transformed by the introduction of the anti-VEGF monoclonal antibody treatments ranibizumab [1] and aflibercept [2] in the 2010s. In 2022, a new molecule, Faricimab, proved its efficacy in exudative AMD. It is a bi-specific monoclonal antibody against VEGF-A and ANG2. The drug has been granted marketing authorization in France, with reimbursement due to begin in October 2023 for naïve patients as well as for those already treated with ranibizumab or aflibercept. The main advantage of this compound [3] is that it extends the injection interval in the Treat and Extend (T&E) protocol, which is more extensive than with previous anti-VEGF agents.

The patients included in the faricimab Phase III study were all naïve to any anti-VEGF treatment. In practice, faricimab is likely to offer hope to patients already treated with anti-VEGF with a short injection interval to lengthen the number of weeks between injections.

As the treatment will be on sale in pharmacies from October 2023, a switch study from previous anti-VEGF drugs to faricimab would contribute to an initial real-life evaluation of the drug in this indication.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female patient of legal age (≥18 years) with exudative AMD treated with IVTranibizumab or aflibercept > 1 year.

  • Patient whose IVT injection interval is strictly less than 12 weeks.

Exclusion

Exclusion Criteria:

  • Severe myopia (axial length > 26 mm or sphere < - 6 dioptres).

  • Presence of angioid striae.

  • Presence of moderate or more severe diabetic retinopathy.

  • History of diabetic macular edema.

  • History of uveitis.

  • Previous retinal vein occlusion (branch or central vein).

  • History of pseudovitelliform macular dystrophy.

  • Patient under guardianship or trusteeship

  • Pregnant or breast-feeding woman

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Faricimab
Phase:
Study Start date:
April 01, 2024
Estimated Completion Date:
September 30, 2026

Connect with a study center

  • Ducloyer

    Nantes, 44000
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.